Medicines as Global Public Goods: The Historical Evolution of and Contemporary Debates on Technological Innovation for Global Health

Suerie Moon

No 36, CID Working Papers from Center for International Development at Harvard University

Abstract: The development of new technologies to combat disease, whether drugs, diagnostics, vaccines, or other health tools, has long been an important part of public health efforts. This paper traces the evolution over the past century of governance regimes for new product development (NPD) for health, using the case of anti-malaria tools as an illustration. There have been major shifts in conceptions about who should benefit from, and who should pay for NPD, with gradual movement away from a primarily national to an increasingly global approach. Innovative institutional arrangements, such as the 'public-private product development partnerships (PDPs),' have begun to take into account the need to develop tools that are adapted for use in developing countries, and to incorporate considerations of affordability into the early stages of development. However, thus far such efforts have been limited to a small set of infectious diseases. The PDPs, as currently organized, are not likely to be the appropriate model for providing NPD to counter the rapidly rising burden in developing countries of chronic non-infectious conditions such as heart disease and mental illness. At the same time, the debate over access to HIV/AIDS drugs has contributed to global norms that frame health tools as global public goods; therefore, political mobilization to demand access to tools with significant therapeutic benefit is likely to rise. To meet the coming epidemiological and political challenges, a new wave of innovation in the governance of NPD will be necessary, based on two key principles: 1) that tools should be adapted and accessible to a global population of end-users (as with the PDPs), and 2) that contributions to NPD, whether of human, scientific, or financial capital, should be a globally-shared burden.

Keywords: global health; access to medicines; global public goods; research & development (R&D); global health governance; intellectual property rights; malaria (search for similar items in EconPapers)
JEL-codes: H41 I18 N30 O34 O38 (search for similar items in EconPapers)
Date: 2009-05
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.hks.harvard.edu/sites/default/files/ce ... ing_papers/036-2.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cid:wpfacu:36

Access Statistics for this paper

More papers in CID Working Papers from Center for International Development at Harvard University 79 John F. Kennedy Street. Contact information at EDIRC.
Bibliographic data for series maintained by Chuck McKenney ().